Abstract Objective To evaluate the efficacy and safety of infliximab in the treatment of Crohn's disease in children. Methods Thirteen children who were diagnosed with Crohn's disease and received routine comprehensive treatment and infliximab (5 mg/kg) between January 2011 and December 2014 were enrolled. The changes in their clinical manifestations, laboratory indices, and Pediatric Crohn's Disease Activity Index (PCDAI) after the 30-week treatment were analyzed retrospectively. Meanwhile, endoscopy was performed to evaluate therapeutic effects. Results The symptoms such as abdominal pain, diarrhea, and bloody stool were relieved soon after infliximab treatment, with no recurrence observed;after the 30-week treatment, the white blood cell count, erythrocyte sedimentation rate, C-reactive protein, and the PCDAI decreased, while the hemoglobin increased significantly compared with those before treatment (PConclusions Infliximab treatment has significant clinical effects in children with Crohn's disease, with no obvious adverse reactions, and therefore, it can be applied as one of the preferred alternatives for treatment of Crohn's disease in children.
Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients:Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry[J]. Dtsch Arztebl Int, 2015, 112(8):121-127.
[3]
Randall C, Vizuete J, Wendorf G, et al. Current and emerging strategies in the management of Crohn's disease[J]. Best Pract Res Clin Gastroenterol, 2012, 26(5):601-610.
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial[J]. LANCET, 2002, 359(9317):1541-1549.
[9]
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease:a prospective multicentre study. Groupe d'Etudes Theraeutiques des Affections Inflammatoires du Tube Digestif (GETAID)[J]. Gut, 1989, 30(7):983-989.
[10]
Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6):1756-1767.
[11]
even G, Assaad A, Biehl T, et al. Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis[J]. World J Gastroenterol, 2012, 18(36):5135-5137.
[12]
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1):46-54.
[13]
Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease:top-down or step-up?[J]. Dig Dis, 2007, 25(3):260-266.
[14]
Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease[J]. Clin Gastroenterol Hepatol, 2015, 13(7):1293-1301.
[15]
Poullenot F, Laharie D. First line therapy of inflammatory bowel disease[J]. Rev Prat, 2014, 64(9):1242-1248.
[16]
Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases:a huge review[J]. Minerva Gastroenterol Dietol, 2010, 56(2):233-243.
[17]
Fernandes C, Allocca M, Danese S, et al. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease[J]. Immunotherapy, 2015, 7(2):175-190.
[18]
Vatansever A, Çekiç C, Ekinci N, et al. Effects of mucosal TNFalpha levels on treatment response in Crohn's disease patients receiving anti-TNF treatment[J]. Hepatogastroenterology, 2014, 61(136):2277-2282.
Moss AC, Fernandez Becker N, Jo Kim K, et al. The impact of infliximab infusion reactions on long-term outcomes inpatients with Crohn's disease[J]. Aliment Pharmacol Ther, 2008, 28(2):221-227.
[21]
Han PD, Cohen RD. Managing immunogenic responses to Infliximab:treatment implications for patients with Crohn's disease[J]. Drugs, 2004, 64(16):1767-1777.
[22]
Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors-state of knowledge[J]. Arch Med Sci, 2014, 22, 10(6):1175-1185.
[23]
Uyanikoglu A, Ermis F, Akyuz F, et al. Infliximab in inflammatory bowel disease:attention to adverse events[J]. Eur Rev Med Pharmacol Sci, 2014, 18(16):2337-2342.
[24]
O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2014, 20(1):1-6.
